piwik-script

Deutsch Intern
    Institute for Clinical Epidemiology and Biometry

    PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)

    PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)

    Coordinator PRESTIGE-AF :

    Roland Veltkamp, Imperial College London, UK

    Coordination of WP 6 (predictive modelling):

    Prof. Peter Heuschmann, Dr. Kirsten Haas, Viktoria Rücker

    Founder:

    European Union Research and Innovation programme Horizon 2020

    Status:

    ongoing, planing of recruitment of patients

    Intracerebral haemorrhage (ICH) is a severe type of stroke with a higher risk of severe disability or recurrent ICH compared to other types of stroke. Moreover, ICH-patients with concomitant atrial fibrillation (AF) are also at a high risk of ischaemic stroke (IS). Recent systematic reviews of observational studies suggest that anticoagulation is beneficial, however optimal stroke prevention in ICH patients with AF remains to be established.

    PRESTIGE-AF is an international, multi-centre, open, parallel-group, prospective randomised clinical trial lead by Prof. Roland Veltkamp, Imperial College, London. The PRESTIGE-AF project will be performed in 8 European countries aiming to:

    a) 

    determine whether direct oral anticoagulant (DOACs) are an effective and safe option for stroke prevention in patients with ICH and AF

    b)

    improve personalized risk prediction for recurrent events by multidimensional clinical, biological and imaging data

    c)

    determine public health and economic implications of a potential intervention

    d)

    investigate patient-centred aspects (attitudes/beliefs and psychosocial status) of preventive medicine including the impact of gender.

    Within PRESTIGE-AF patients with recent ICH and atrial fibrillation from 6 European countries will be recruited and randomised in an intervention group (DOACs) and a control group (no anticoagulation). Follow-up visits will take place after 1, 6, 12, 24, 36 months. To address the objectives of the study several sub-studies based on the randomised clinical trial will be conducted.

    Within the sub-study “predictive modelling of risk” the Institute of Clinical Epidemiology and Biometry will develop an individual risk prediction model for recurrent stroke based on extensive patient characteristics. In a second step the model will be expanded by adding relevant biological information (biomarkers, genotyping) and neurological information from imaging. In the future a comprehensive model can be used to derive recommendations for optimal guidance of individual preventive strategies in ICH patients with atrial fibrillation.

     

    Information about the project can be found at:

     

    https://www.prestige-af.org/